Inspyr Therapeutics, Inc. Stock Price - NSPX

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Inspyr Therapeutics, Inc. (QB) NSPX OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.0019 0.00 0.00 0.00 0.0019 20:00:00
Bid Price Ask Price Spread Spread % News
0.0014 0.0024 0.001 41.67% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Inspyr Therapeutics, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 285.00k 150.00M $ -11.10M - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
9.99k $ - 0.00% - -

more financials information »

Inspyr Therapeutics, Inc. News

Loading Messages....

Latest NSPX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NSPX Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0000.00000--
1 Month0.00360.00450.00150.00252M-0.0017-47.22%
3 Months0.00390.00580.00150.0036656k-0.002-51.28%
6 Months0.00450.00790.00150.0041783k-0.0026-57.78%
1 Year0.0050.013050.00150.00523M-0.0031-62.00%
3 Years0.124.990.00150.00641M-0.1181-98.42%
5 Years0.74.990.00150.0270654k-0.6981-99.73%

Inspyr Therapeutics, Inc. Description

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.

Your Recent History
Inspyr The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.